{"entity":{"id":"nct06232096","kind":"trial","name":"A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.","aka":[],"tldr":"A phase 1/2 trial of MBS314 Injection in multiple myeloma, run by Beijing Mabworks Biotech Co., Ltd., now recruiting.","summary":"A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma. is a phase 1/2 interventional study registered as NCT06232096 by Beijing Mabworks Biotech Co., Ltd., with 154 participants planned, started 2024-02-22 and due to reach its primary completion in 2026-02. Interventions recorded: MBS314 Injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06232096","url":"https://clinicaltrials.gov/study/NCT06232096"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["multiple-myeloma","myeloma-relapsed-refractory"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["beijing-mabworks-biotech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06232096","phase":"1/2","setting":"A Phase Ⅰ/Ⅱ Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of MBS314 Injection in Patients With Relapsed/Refractory Multiple Myeloma.","sponsor":"Beijing Mabworks Biotech Co., Ltd.","started":"2024-02-22","startedType":"actual","enrolled":154,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06232096/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"myeloma-relapsed-refractory","kind":"cancer","name":"Relapsed or refractory multiple myeloma","route":"/cancers/myeloma-relapsed-refractory/"}],"company":[{"id":"beijing-mabworks-biotech","kind":"company","name":"Beijing Mabworks Biotech","route":"/companies/beijing-mabworks-biotech/"}]}}